Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: May 25, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,908,838

« Back to Dashboard

Which drugs does patent 5,908,838 protect, and when does it expire?


Patent 5,908,838 protects SOLODYN and XIMINO and is included in two NDAs. There have been four Paragraph IV challenges on Solodyn.

Summary for Patent: 5,908,838

Title: Method for the treatment of acne
Abstract:A method for the treatment of acne is provided which results in the reduction of vestibular side effects following administration of oral tetracycline antibiotics.
Inventor(s): Gans; Eugene H. (Phoenix, AZ)
Assignee: Medics Pharmaceutical Corporation (Phoenix, AZ)
Application Number:09/028,871
Patent Claim Types:
see list of patent claims
Use; Dosage form; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Medicis
SOLODYN
minocycline hydrochloride
TABLET, EXTENDED RELEASE;ORAL050808-001May 8, 2006DISCNYesNo5,908,838► Subscribe TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
Medicis
SOLODYN
minocycline hydrochloride
TABLET, EXTENDED RELEASE;ORAL050808-008Aug 27, 2010RXYesNo5,908,838► Subscribe TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
Medicis
SOLODYN
minocycline hydrochloride
TABLET, EXTENDED RELEASE;ORAL050808-004Jul 23, 2009RXYesNo5,908,838► Subscribe TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
Medicis
SOLODYN
minocycline hydrochloride
TABLET, EXTENDED RELEASE;ORAL050808-007Aug 27, 2010ABRXYesNo5,908,838► Subscribe TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
Medicis
SOLODYN
minocycline hydrochloride
TABLET, EXTENDED RELEASE;ORAL050808-002May 8, 2006DISCNYesNo5,908,838► Subscribe TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot